Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Reimbursement Briefs: 340B, Exchange Plan Cost-Sharing, Part D Dual Eligibles

Executive Summary

HRSA’s Office of Pharmacy Affairs adds a new branch to oversee compliance in the 340B drug discount program; a PhRMA-funded study finds high coinsurance for drugs used by enrollees in many state exchange plans; OIG says Part D plans are covering a high percentage of drugs used by Medicare/Medicaid dual eligibles.

You may also be interested in...

Part D Plans Offer Broad Drug Access For Dual Eligibles, With Some Exceptions - OIG Study

Vytorin, Lunesta and Avapro are among eight drugs that are covered by fewer than 75% of plans available to beneficiaries eligible for both Medicare and Medicaid.

GSK's Nucala Is Significantly Overpriced, ICER Draft Report Finds

New biologic for severe asthma doesn't stack up well to standard of care on generally accepted levels of cost per quality-adjusted life year.

Deal Watch: Sanofi, Boehringer Swap Side Businesses

Busy week for AstraZeneca sees buyout of Acerta and acquisition of remaining Daliresp/Daxas worldwide rights from Takeda. Amgen and GSK undo their cancer drug alliances from 2009 and 2010, with all rights reverting to the big biotech.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts